

Tetraphase Pharmaceuticals Investor Relations Department 480 Arsenal Street, Suite 110 Watertown, MA 02472 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: TTPH	
Last Trade:	6.47
Trade Time:	4:00 PM ET Oct 20, 2017
Change:	0.07 1 (+1.094%)
Day Range	6.33 - 6.55
52-Week Range	3.11 - 9.93
Volume	272,911


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Since the company's inception, Tetraphase has developed a robust antibiotics platform based on the tetracycline core chemical structure, which offers the potential to dramatically improve the treatment of serious bacterial infections. Tetraphase has utilized this fully-synthetic chemistry technology to create a pipeline of novel tetracycline antibiotics, particularly those with activity against the toughest multidrug-resistant Gramnegative bacteria.

... (more)

Stock Information



Press Releases [View all]

Oct 16, 2017

<u>Tetraphase Pharmaceuticals Appoints Kam</u> <u>Unninayar as Chief Financial Officer</u>

Oct 4, 2017

Tetraphase Pharmaceuticals Presents
Clinical Data from Oral Eravacycline
Development Program at IDWeek 2017

Sep 25, 2017

<u>Tetraphase Pharmaceuticals to Present Data</u> at IDWeek 2017

Sep 11, 2017

Tetraphase Pharmaceuticals Completes

Enrollment of IGNITE3 Phase 3 Clinical Trial
of Eravacycline in Complicated Urinary Tract
Infections

Sep 5, 2017

Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences

Financials & Filings [View all]

Mar 13, 2017 Annual Report (10-K)

Apr 21, 2017
Proxy Statement (DEF 14A)

Aug 2, 2017 Quarterly Report (10-Q)

May 8, 2017 Quarterly Report (10-Q)

Nov 3, 2016 Quarterly Report (10-Q)